PL3359564T3 - Przeciwciała, które silnie neutralizują wirusa zapalenia wątroby typu B i ich zastosowania - Google Patents

Przeciwciała, które silnie neutralizują wirusa zapalenia wątroby typu B i ich zastosowania

Info

Publication number
PL3359564T3
PL3359564T3 PL16779075T PL16779075T PL3359564T3 PL 3359564 T3 PL3359564 T3 PL 3359564T3 PL 16779075 T PL16779075 T PL 16779075T PL 16779075 T PL16779075 T PL 16779075T PL 3359564 T3 PL3359564 T3 PL 3359564T3
Authority
PL
Poland
Prior art keywords
antibodies
virus
potently neutralize
neutralize hepatitis
hepatitis
Prior art date
Application number
PL16779075T
Other languages
English (en)
Inventor
Davide Corti
Original Assignee
Humabs Biomed S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed S.A. filed Critical Humabs Biomed S.A.
Publication of PL3359564T3 publication Critical patent/PL3359564T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL16779075T 2015-10-07 2016-10-07 Przeciwciała, które silnie neutralizują wirusa zapalenia wątroby typu B i ich zastosowania PL3359564T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2015/001970 WO2017059878A1 (en) 2015-10-07 2015-10-07 Antibodies that potently neutralize hepatitis b virus and uses thereof
EP16779075.7A EP3359564B1 (en) 2015-10-07 2016-10-07 Antibodies that potently neutralize hepatitis b virus and uses thereof
PCT/EP2016/074114 WO2017060504A1 (en) 2015-10-07 2016-10-07 Antibodies that potently neutralize hepatitis b virus and uses thereof

Publications (1)

Publication Number Publication Date
PL3359564T3 true PL3359564T3 (pl) 2020-11-30

Family

ID=54330711

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16779075T PL3359564T3 (pl) 2015-10-07 2016-10-07 Przeciwciała, które silnie neutralizują wirusa zapalenia wątroby typu B i ich zastosowania

Country Status (24)

Country Link
US (3) US10683344B2 (pl)
EP (2) EP3359564B1 (pl)
JP (4) JP6869968B2 (pl)
KR (1) KR102725168B1 (pl)
CN (3) CN108137675B (pl)
AU (1) AU2016334735B2 (pl)
BR (1) BR112018002406A2 (pl)
CA (1) CA2993745A1 (pl)
CY (1) CY1123462T1 (pl)
DK (1) DK3359564T3 (pl)
EA (1) EA038301B1 (pl)
ES (1) ES2813927T3 (pl)
HR (1) HRP20201345T1 (pl)
HU (1) HUE050231T2 (pl)
IL (1) IL258326B (pl)
LT (1) LT3359564T (pl)
MX (1) MX2018004127A (pl)
MY (1) MY187161A (pl)
PH (1) PH12018500199A1 (pl)
PL (1) PL3359564T3 (pl)
PT (1) PT3359564T (pl)
SI (1) SI3359564T1 (pl)
WO (2) WO2017059878A1 (pl)
ZA (1) ZA201800710B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
CA3099726A1 (en) * 2018-05-10 2019-11-14 Clearb Therapeutics Ltd. Methods and compositions for the treatment of hepatitis b infection
WO2019222506A1 (en) * 2018-05-16 2019-11-21 Chang Gung Memorial Hospital, Linkou Novel leucine-rich repeat neuronal protein 1 (lrrn1) antibodies and uses thereof
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
KR20210100115A (ko) 2018-12-03 2021-08-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 올리고-벤즈아미드 유사체 및 암 치료에서의 이의 용도
PH12021551458A1 (en) * 2018-12-19 2022-05-02 Humabs Biomed Sa Antibodies that neutralize hepatitis b virus and uses thereof
PL4285929T3 (pl) 2018-12-20 2026-03-23 Humabs Biomed Sa Terapia skojarzona hbv
KR102084912B1 (ko) * 2019-01-17 2020-03-05 주식회사 녹십자 B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체
CA3145057A1 (en) 2019-07-20 2021-01-28 Wenhui Li A method of treating hbv infection by using anti-pre-s1 hbv antibodies
EP4021578A1 (en) 2019-08-29 2022-07-06 VIR Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
CN113717283B (zh) * 2020-05-25 2023-05-26 厦门万泰凯瑞生物技术有限公司 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用
KR20230034978A (ko) * 2020-06-02 2023-03-10 가부시키가이샤 알씨엠지 Hbv의 항rna 바이러스 입자 항체
US20230340081A1 (en) * 2020-06-08 2023-10-26 Hoffmann-La Roche Inc. Anti-hbv antibodies and methods of use
JP2023531682A (ja) * 2020-06-22 2023-07-25 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｄ型肝炎ウイルス感染の処置のための組成物および方法
US20230242621A1 (en) * 2020-06-24 2023-08-03 Vir Biotechnology, Inc. Engineered hepatitis b virus neutralizing antibodies and uses thereof
CN113912706A (zh) * 2020-07-09 2022-01-11 北京凯因科技股份有限公司 结合乙型肝炎病毒表面抗原的抗体及其应用
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP2024504167A (ja) 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
CN113234144B (zh) * 2021-05-26 2022-02-25 武汉工程大学 一种人源性抗乙肝表面抗原的单链抗体、制剂、编码基因、载体质粒及宿主细胞
US20240327500A1 (en) * 2021-07-15 2024-10-03 National University Of Singapore Anti-hbv antibodies and uses thereof
CN113777312B (zh) * 2021-09-03 2024-02-02 普十生物科技(北京)有限公司 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用
US20240391979A1 (en) * 2021-09-13 2024-11-28 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
CA3242060A1 (en) * 2021-12-21 2023-06-29 Hbvtech, Llc. Methods for eliminating hepatitis b virus cccdna and rcdna and the hepatitis b drugs used in the methods thereof
AR129399A1 (es) 2022-05-23 2024-08-21 Vir Biotechnology Inc Anticuerpos diseñados neutralizantes del virus de la hepatitis b y usos de los mismos
CN116162153B (zh) * 2022-09-01 2024-09-10 复旦大学附属中山医院 一种乙肝病毒表面抗原的单克隆抗体及其应用
CN118725092B (zh) * 2023-03-28 2025-08-12 东莞市朋志生物科技有限公司 抗HBs-Ag抗体、检测HBs-Ag的试剂和试剂盒
CN121487748A (zh) * 2023-05-31 2026-02-06 蓝樫鸟医药公司 用于治疗慢性丁型肝炎的抗HBsAg抗体
CN119143869A (zh) * 2023-06-16 2024-12-17 复旦大学 乙肝病毒表面抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1997039029A2 (en) 1996-04-18 1997-10-23 Abbott Laboratories An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
JP2001508054A (ja) * 1996-12-30 2001-06-19 イノジェネティックス・ナムローゼ・フェンノートシャップ ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
CA2530388A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
CA2594922A1 (en) * 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
US20090252729A1 (en) 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
KR20090056537A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물
NZ592036A (en) 2008-10-22 2012-12-21 Inst Research In Biomedicine Methods for producing antibodies from plasma cells
TWI620568B (zh) * 2012-08-30 2018-04-11 雷普利可公司 用於治療ｂ型肝炎及ｄ型肝炎感染之方法
WO2014072526A1 (en) 2012-11-12 2014-05-15 Ruprecht-Karls-Universität Heidelberg Development of hbv- and/or hdv-susceptible cells, cell lines and non-human animals
WO2015107126A1 (en) * 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof

Also Published As

Publication number Publication date
ZA201800710B (en) 2019-05-29
HRP20201345T1 (hr) 2020-11-27
NZ739360A (en) 2024-10-25
HK1256869A1 (en) 2019-10-04
CA2993745A1 (en) 2017-04-13
KR20180056777A (ko) 2018-05-29
KR102725168B1 (ko) 2024-10-31
JP2018535650A (ja) 2018-12-06
US20230303663A1 (en) 2023-09-28
AU2016334735B2 (en) 2022-10-27
CN114539391A (zh) 2022-05-27
SI3359564T1 (sl) 2020-10-30
DK3359564T3 (da) 2020-08-17
JP6869968B2 (ja) 2021-05-12
MY187161A (en) 2021-09-06
IL258326A (en) 2018-05-31
PT3359564T (pt) 2020-09-04
HUE050231T2 (hu) 2020-11-30
EP3359564A1 (en) 2018-08-15
EP3753949A1 (en) 2020-12-23
AU2016334735A1 (en) 2018-02-15
EP3359564B1 (en) 2020-06-03
PH12018500199A1 (en) 2018-08-13
US10683344B2 (en) 2020-06-16
US20210040183A1 (en) 2021-02-11
CN114539392B (zh) 2024-01-26
JP7171809B2 (ja) 2022-11-15
LT3359564T (lt) 2020-10-26
MX2018004127A (es) 2018-06-13
CN114539392A (zh) 2022-05-27
JP2024097078A (ja) 2024-07-17
US12037381B2 (en) 2024-07-16
JP2021121188A (ja) 2021-08-26
US20190016785A1 (en) 2019-01-17
CY1123462T1 (el) 2022-03-24
EA201890874A1 (ru) 2018-11-30
WO2017059878A1 (en) 2017-04-13
ES2813927T3 (es) 2021-03-25
CN108137675A (zh) 2018-06-08
EA038301B1 (ru) 2021-08-06
WO2017060504A1 (en) 2017-04-13
JP2023011809A (ja) 2023-01-24
CN108137675B (zh) 2022-03-22
BR112018002406A2 (pt) 2018-09-18
US11390664B2 (en) 2022-07-19
IL258326B (en) 2021-10-31

Similar Documents

Publication Publication Date Title
IL258326B (en) Antibodies that neutralize the hepatitis b virus in potency and their uses
IL283321A (en) Antibodies against muc16 and their uses
IL258284A (en) Anti-Lag 3 antibodies and their uses
IL255961B (en) Anti-cd40 antibodies and uses thereof
IL257263A (en) Antibodies against angptl8 and their use
ZA201800536B (en) Il-8-binding antibodies and uses thereof
HUE056243T2 (hu) Emberi immunhiányt okozó vírust semlegesítõ ellenanyagok
SG11201803474UA (en) Vaccines against hepatitis b virus
IL254534B (en) Anti-ceacam6 antibodies and uses thereof
IL254954A0 (en) Anti-pacap antibodies and their uses
PT3292154T (pt) Anticorpos anti-her3 humano e seus usos
IL249660A0 (en) Methods for treating hepatitis b virus and hepatitis d virus infections
LT3220947T (lt) Antikūnai, galintys neutralizuoti pasiutligės virusą ir kitus lisavirusus bei jų panaudojimas
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
IL267785A (en) virus
GB201702193D0 (en) Hepatitis E virus vaccine
GB201600382D0 (en) Engineered virus
GB201716047D0 (en) Virus
GB201708779D0 (en) Virus and method
GB201708778D0 (en) Virus and method
GB201600380D0 (en) Modified virus
GB201700259D0 (en) Virus